Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
fda
3
×
life sciences
national blog main
alexion pharmaceuticals
biotech
boston
clinical trials
deals
national top stories
ucb
alex azar
alliance for aging research
alnylam pharmaceuticals
amgen
amyotrophic lateral sclerosis (als)
autoimmune disorders
biogen
biotechnology innovation organization
boehringer ingelheim
boulder/denver blog main
boulder/denver top stories
complement system
detroit blog main
detroit top stories
dicerna pharamceuticals
drug pricing
duane schulthess
eli lilly
erica whittaker
generalized myasthenia gravis
hepatitis b
hepatitis b virus
hereditary transthyretin amyloidosis
immune-mediated necrotizing myopathy
indiana blog main
indiana top stories
jim greenwood
medicaid
What
drug
3
×
pharma
3
×
disease
medicines
pharmaceuticals
administration
alternative
angry
anti
autoimmune
benefited
candidate
caught
causing
deal
despite
dicerna
expensive
eye
fear
gene
hepatitis
industry
intended
lead
losing
pay
plans
potential
presidential
price
producing
protein
ra
research
rhetoric
roche
rx
scalps
split
Language
unset
Current search:
pharma
×
fda
×
drug
×
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
@xconomy.com
5 years ago
Losing “Scalps”? Despite Pharma Fear, A Split on Trump Rx-Price Plans